| Identification | Back Directory | [Name]
Imexon | [CAS]
59643-91-3 | [Synonyms]
imexon
bm06002
AMpliMexon
Imexon
(Amplimexon
4-IMINO-1,3-DIAZABICYCLO-[3.1.0]HEXAN-2-ONE
4-Amino-1,3-diazabicyclo[3.1.0]hex-3-en-2-one
1,3-Diazabicyclo[3.1.0]hex-3-en-2-one, 4-amino- | [EINECS(EC#)]
261-838-2 | [Molecular Formula]
C4H5N3O | [MDL Number]
MFCD00056850 | [MOL File]
59643-91-3.mol | [Molecular Weight]
111.1 |
| Chemical Properties | Back Directory | [Boiling point ]
231.6±23.0 °C(Predicted) | [density ]
2.26±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
4.79±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Cancer chemotherapy. | [Brand name]
Amplimexon
(Amplimed). | [in vivo]
Imexon (BM 06002) in combination with DTIC results in an increase in the peak plasma imexon level in non-tumor-bearing mice. The combination of both drugs increases plasma imexon AUC by 22% (p=0.026). Imexon (BM 06002) (100 mg/kg/day, i.v.) treatment decreases the body weight of SCID mice bearing human A375 melanoma tumors, but there is no significant difference in tumor growth[2]. Imexon (BM 06002) (100 mg/kg) in combination with GEM shows synergistic inhibition of Panc-1 tumor growth in SCID mice. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
|